Debra Yu, MD is Managing Director and Head of Cross Border Healthcare Investment Banking at China Renaissance Securities (US), a global investment bank with offices in Beijing, Shanghai, Hong Kong and New York. She has 30 years of experience in the life sciences industry where she has been a VC investor, a company executive and a strategic advisor to companies worldwide. Previously she was Managing Director of Labrador Advisors, where she advised clients in multiple life sciences industry sub-segments including biopharma, specialty pharma, medtech, research instrumentation and diagnostics and executed numerous successful business development transactions in the US and in China.
Earlier, Debra helped architect and co-led the
Pfizer venture capital group and was General Partner of Delphi Ventures and Managing Director of Bay City Capital. She also served as acting CEO of Molecular Applications Group and managed its strategic sale. Her interest in China led her to serve as VP Strategy for WuxiApptec, a leading Chinese CRO.
Debra began her industry training at Morgan Stanley in the venture capital group. She later joined McKinsey & Co., in New York and London as a core member of the Healthcare practice leadership team.
She received a BA with high honors in Molecular Biology from Princeton University earned an MD from Harvard Medical School. She currently serves on the board of Bayhelix, a China-U.S. cross-border life sciences leadership organization. Debra is also a Governor of the Asian American Alumni Association of Princeton University.